EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rethinking CFTR variant responsiveness: Differential responses to vanzacaftor and elexacaftor

Noelia Rodriguez Mier, Isabelle Callebaut, Marijke Proesmans, Eva Van Braeckel, Stephanie Van Biervliet, Mieke Boon, Anabela Santo Ramalho, François Vermeulen

Journal of Cystic Fibrosis · 2026-03 · 25 (2) · 314-318

DOI: 10.1016/j.jcf.2025.12.018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2026-03. Verfasst von Noelia Rodriguez Mier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Development and Regeneration, Woman and Child Unit, CF research lab, KU Leuven, Leuven, Belgium; Department of Paediatrics, Paediatric …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, Indoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: King Baudouin Foundation, KU Leuven.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) care has been revolutionized by CFTR modulators, particularly the triple combination elexacaftor/tezacaftor/ivacaftor (ETI). However, a subset of people with CF (pwCF) carrying ETI-unresponsive variants still lack effective therapies. A nextgeneration modulator combination, vanzacaftor/tezacaftor/deutivacaftor (VTD), shows promise in addressing this gap. Phase 3 trials report superior efficacy of VTD in reducing sweat chloride and suggest potential benefit for 31 CFTR variants previously deemed ETI-unresponsive based on limited in vitro data. Reassessment of these variants reveals that some demonstrate residual function or borderline ETI responsiveness, challenging their unresponsive classification. Differences in molecular interactions, particularly within NBD1 and modulator-binding sites, may account for variant-specific responses. Patient-derived intestinal organoid (PDIO) assays showed significant functional improvement with VTD, but not ETI, in 2 pwCF with G458V and G85R mutations, supporting the notion of distinct mechanisms of action. These findings underscore the need to refine CFTR variant classifications and highlight the limitations of current in vitro thresholds. While PDIOs offer physiologically relevant insights, clinical outcomes remain the ultimate determinant of therapeutic benefit. Broader access to raw data and individualized in vitro-clinical correlations are essential for informed therapeutic decisions. VTD offers new hope for pwCF with rare or previously unresponsive variants, reinforcing the importance of a personalized, datadriven approach to CF care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesIndolesPyridinesPyrazolesPyrrolesAminophenolsHumansQuinolonesDrug CombinationsChloride Channel AgonistsPyrrolidines

Stichwörter der Autor:innen

CFTR modulatorsCystic fibrosisElexacaftorIn vitro functional assaysPatientderived intestinal organoidsPersonalized therapyRare CFTR variantsTheratypingVanzacaftor

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorelexacaftorBenzodioxolesIndolesPyridinesPyrazolesQuinolonesPyrrolesDrug CombinationsAminophenols

Autor:innen und Institutionen

  • Department of Development and Regeneration, Woman and Child Unit, CF research lab, KU Leuven, Leuven, Belgium; Department of Paediatrics, Paediatric Pulmonology, University Hospital Leuven, Leuven, Belgium. Electronic a…
  • Muséum National d'Histoire Naturelle, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, Sorbonne Université, Paris F-75005, France.
  • Department of Development and Regeneration, Woman and Child Unit, CF research lab, KU Leuven, Leuven, Belgium; Department of Paediatrics, Paediatric Pulmonology, University Hospital Leuven, Leuven, Belgium.
  • Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium.
  • Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium; Department of Paediatrics, Ghent University Hospital, Ghent, Belgium.
  • Department of Development and Regeneration, Woman and Child Unit, CF research lab, KU Leuven, Leuven, Belgium.

Förderung

  • King Baudouin Foundation
  • KU Leuven

Zitieren

APA

Rodriguez Mier, N., Callebaut, I., Proesmans, M., Van Braeckel, E., Van Biervliet, S., Boon, M., Ramalho, A. S., & Vermeulen, F. (2026). Rethinking CFTR variant responsiveness: Differential responses to vanzacaftor and elexacaftor. Journal of Cystic Fibrosis, 25(2), 314-318. https://doi.org/10.1016/j.jcf.2025.12.018

Vancouver

Rodriguez Mier N, Callebaut I, Proesmans M, Van Braeckel E, Van Biervliet S, Boon M, et al. Rethinking CFTR variant responsiveness: Differential responses to vanzacaftor and elexacaftor. Journal of Cystic Fibrosis. 2026;25(2):314-318. doi:10.1016/j.jcf.2025.12.018

BibTeX
@article{RodriguezMier2026,
  author = {Rodriguez Mier, Noelia and Callebaut, Isabelle and Proesmans, Marijke and Van Braeckel, Eva and Van Biervliet, Stephanie and Boon, Mieke and Ramalho, Anabela Santo and Vermeulen, François},
  title = {Rethinking CFTR variant responsiveness: Differential responses to vanzacaftor and elexacaftor},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {314--318},
  doi = {10.1016/j.jcf.2025.12.018}
}
Kostenlos starten →